The health-care reform proposed by US Senate Democrats, led by Senate Majority Leader Harry Reid (Democrat, Nevada), to extend coverage to 94% of eligible Americans, will cost $849 billion over 10 years, Senate leaders said yesterday, and slash the deficit by $127 billion over the next decade. The cost would also be considerably less than the $1,100 billion anticipated from the reforms passed recently by the House of Representatives (The Pharma Letter November 9).
While the House plans an income surtax on the wealthiest Americans, much of the funding for the Senate bill will come from a tax on high-end insurance. That so-called Cadillac tax would be assessed for plans valued at $8,500 for individuals or $23,000 for families, with higher thresholds for high-risk workers and people living in states with costlier premiums, comments the Bloomberg news service. Senator Reid settled on a Medicare payroll tax increase for some Americans, raising the rate to 1.95% from 1.45% for couples earning more than $250,000.
CBO/JCT estimates
The Senate bill got a major boost from an analysis by the Congressional Budget Office (CBO) and the staff of the Joint Committee on Taxation (JCT) of both the House and Senate proposals, which estimated the federal budget deficit could be cut by $127 billion over 10 years by the latter. The Senate bill would also cut the deficit by $650 million in the second decade, it was noted.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze